DeepMed Research

GILEAD SCIENCES SL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 1

Terminated

Conditions: Gastric Adenocarcinoma

Interventions: Drug: Andecaliximab
Drug: S-1
Drug: Nivolumab
Drug: Cisplatin
Drug: Oxaliplatin

First Posted Date: 2016-08-11

Last Posted Date: 2020-12-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 36

Registration Number: NCT02862535

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

Phase 1

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Vesatolimod
Drug: Placebo
Drug: ARV regimen

First Posted Date: 2016-08-08

Last Posted Date: 2020-02-21

Lead Sponsor: Gilead Sciences

Target Recruit Count: 48

Registration Number: NCT02858401

Locations: 🇺🇸
Midway Immunology & Research Center, Fort Pierce, Florida, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Mills Clinical Research, Los Angeles, California, United States

and more 5 locations

Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis

Phase 2

Completed

Conditions: Nonalcoholic Steatohepatitis (NASH)

Interventions: Drug: Firsocostat
Drug: Placebo

First Posted Date: 2016-08-05

Last Posted Date: 2020-07-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 127

Registration Number: NCT02856555

Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)

Phase 2

Completed

Conditions: Alcoholic Hepatitis (AH)

Interventions: Drug: Prednisolone
Drug: Selonsertib
Drug: Placebo

First Posted Date: 2016-08-03

Last Posted Date: 2019-02-06

Lead Sponsor: Gilead Sciences

Target Recruit Count: 104

Registration Number: NCT02854631

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States
🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 41 locations

Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

Phase 2

Completed

Conditions: Nonalcoholic Steatohepatitis (NASH)

Interventions: Drug: GS-9674
Drug: Placebo to match GS-9674

First Posted Date: 2016-08-03

Last Posted Date: 2019-01-29

Lead Sponsor: Gilead Sciences

Target Recruit Count: 140

Registration Number: NCT02854605

Locations: 🇨🇦
Toronto Liver Center, Toronto, Ontario, Canada
🇨🇦
LMC Clinical Research Inc (Bayview), Toronto, Ontario, Canada
🇺🇸
Clinical Research of South Florida, Coral Gables, Florida, United States

and more 34 locations

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

Phase 3

Active, not recruiting

Conditions: Pre-Exposure Prophylaxis of HIV-1 Infection

Interventions: Drug: F/TAF
Drug: F/TDF
Drug: F/TAF Placebo
Drug: F/TDF Placebo

First Posted Date: 2016-07-22

Last Posted Date: 2024-10-22

Lead Sponsor: Gilead Sciences

Target Recruit Count: 5399

Registration Number: NCT02842086

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)

Phase 3

Completed

Conditions: HBV
Chronic HBV Infection

Interventions: Drug: TDF
Drug: TAF
Drug: TAF Placebo
Drug: TDF Placebo

First Posted Date: 2016-07-18

Last Posted Date: 2024-10-15

Lead Sponsor: Gilead Sciences

Target Recruit Count: 181

Registration Number: NCT02836249

Locations: 🇨🇳
Beijing Ditan Hospital, Beijing, China
🇨🇳
PLA 302 Hospital, Beijing, China
🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China

and more 22 locations

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)

Phase 3

Completed

Conditions: HBV
Chronic HBV Infection

Interventions: Drug: TAF
Drug: TDF
Drug: TDF Placebo
Drug: TAF Placebo

First Posted Date: 2016-07-18

Last Posted Date: 2024-10-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 155

Registration Number: NCT02836236

Locations: 🇨🇳
Beijing Ditan Hospital, Beijing, China
🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China
🇨🇳
Beijing Youan Hospital, Capital Medical University, Beijing, China

and more 26 locations

Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

Phase 3

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL
Drug: RBV

First Posted Date: 2016-07-04

Last Posted Date: 2018-11-14

Lead Sponsor: Gilead Sciences

Target Recruit Count: 117

Registration Number: NCT02822794

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

Phase 1

Completed

Conditions: Nonalcoholic Steatohepatitis (NASH)
Primary Sclerosing Cholangitis (PSC)

Interventions: Drug: Cilofexor

First Posted Date: 2016-06-21

Last Posted Date: 2021-01-07

Lead Sponsor: Gilead Sciences

Target Recruit Count: 57

Registration Number: NCT02808312

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy